Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
1005-24-1|n/a,n/a|Sequence:1, Age:n/a,Type:none (controls),Quantity:0,Unit:unit code not relevant,Application:Inhalation, Remarks:n/a|41 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-2|n/a,n/a|Sequence:1, Age:n/a,Type:none (controls),Quantity:0,Unit:unit code not relevant,Application:Inhalation, Remarks:n/a|41 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-3|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:30,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 0.061±0.032Gy|74 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-4|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:30,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 0.061±0.032Gy|72 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-5|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:90,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 0.95±0.46Gy|81 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-6|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:90,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 0.95±0.46Gy|85 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-7|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:280,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 3.7±1.6Gy|96 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-8|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:280,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 3.7±1.6Gy|59 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-9|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:850,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 12±2.4Gy|4 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-10|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:850,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 84d, lung alpha dose 12±2.4Gy|12 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-11|n/a,n/a|Sequence:1, Age:n/a,Type:none (controls),Quantity:0,Unit:unit code not relevant,Application:Inhalation, Remarks:n/a|36 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Old Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-12|n/a,n/a|Sequence:1, Age:n/a,Type:none (controls),Quantity:0,Unit:unit code not relevant,Application:Inhalation, Remarks:n/a|40 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Old Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-13|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:280,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 450d, lung alpha dose 0.88±0.62Gy|77 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Old Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-14|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:280,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 450d, lung alpha dose 0.88±0.62Gy|83 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Old Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-15|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:850,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 450d, lung alpha dose 6.7±2.0Gy|18 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Old Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-16|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:850,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Single exposure 450d, lung alpha dose 6.7±2.0Gy|14 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Old Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-17|n/a,n/a|Sequence:1, Age:n/a,Type:none (controls),Quantity:0,Unit:unit code not relevant,Application:Inhalation, Remarks:n/a|51 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-18|n/a,n/a|Sequence:1, Age:n/a,Type:none (controls),Quantity:0,Unit:unit code not relevant,Application:Inhalation, Remarks:n/a|51 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-19|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:26,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Repeated exposure every 60d between 84 and 450d, lung alpha dose 0.9±0.39Gy|81 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-20|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:26,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Repeated exposure every 60d between 84 and 450d, lung alpha dose 0.9±0.39Gy|86 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-21|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:80,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Repeated exposure every 60d between 84 and 450d, lung alpha dose 4.4±1.8Gy|64 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-22|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:80,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Repeated exposure every 60d between 84 and 450d, lung alpha dose 4.4±1.8Gy|55 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-23|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:259,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Repeated exposure every 60d between 84 and 450d, lung alpha dose 10±2.1Gy|45 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Male|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
1005-24-24|n/a,n/a|Sequence:1, Age:n/a,Type:Pu-239 dioxide,Quantity:259,Unit:becquerels initial or established lung burden,Application:Inhalation, Remarks:Repeated exposure every 60d between 84 and 450d, lung alpha dose 10±2.1Gy|49 (0 in ERA)|Rat|Rat CDF (F344) /CrlBR|Female|Young Adult|Lifespan study with histopathology,  lung burdens and retention  by serial sacrifice tissue and whole body counting|No information on individuals available for this study
		
